Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nateglinide

Drug Profile

Nateglinide

Alternative Names: A 4166; AY 4166; Fastic; Glinate; Nategurinide; SDZ DJN 608; Senaglinide; Starlix; Starsis; YM 026

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto
  • Developer Ajinomoto; Astellas Pharma; Glenmark Pharmaceuticals Ltd; Novartis
  • Class Antihyperglycaemics; Aromatic amino acids; Cyclohexanes; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Jul 2016 Generic equivalent approved in USA for Type-2 diabetes mellitus
  • 13 Jun 2016 No development reported - Phase-III for Type-2 diabetes mellitus (Combination therapy, Second-line therapy or greater) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top